Gilead Sciences Lifts FY21 Outlook

Biotechnology company Gilead Sciences, Inc. (GILD) on Thursday raised its outlook for fiscal 2021, helped by strong performance in the third quarter.

The company now expects earnings per share between $5.50 and $5.70, higher than the earlier announced $4.70 and $5.05. Adjusted earnings per share is expected between $7.90 and $8.10, compared to the earlier $6.90 and $7.25.

On average, 26 analysts polled by Thomson Reuters expect the company to post earnings of $7.18 per share for the year.

The company expects total product sales for fiscal 2021 to be between $26.0 billion and $26.3 billion, higher than the earlier $24.4 billion and $25.0 billion, while analysts are looking for revenues of $25.12 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT